Transcriptome Analysis of the Peripheral Blood in CIDP (PHARMACOPID)

Assistance Publique - Hôpitaux de Paris

Status

Unknown

Conditions

Clarkson Syndrome

Muscular Autoimmune Disorders

Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Autoimmune Diseases

Treatments

Drug: IVIg

Study type

Interventional

Funder types

Other

Identifiers

NCT02404298

P111122

Details and patient eligibility

About

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated disorder of peripheral nerves. Intravenous immunoglobulins (IVIg) are a first line therapy for CIDP. The investigators used a transcriptomic approach to compare the gene expression profiles in the peripheral blood of patients having a CIDP or autoimmune diseases, before and after IVIg treatment, in order to identify their mechanism of action in this condition, to lead to a better understanding of CIDP pathophysiology, and potentially determine factors associated with the response to the treatment.

Full description

We study the change of the:

gene profile on transcriptome analysis of peripheral blood
T cell repertory
igG dosage
immunological profile

Before IVIG (T1 time) and and 3 weeks after IVIg treatment (T2 time). On a population of patients having: CIDP, autoimmune muscular disease, Clarkson syndrome, or autoimmune diseases.

We also search for polymorphism of FCgammareceptor, TKPC et CASP3 genes in CIDP patients

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria :

Age ≥ 18 years old
Obtained informed consent
Patient having a definite or probable CIDP according to EFNS/PNS criteria or atypical CIDP corresponding to patients having the EFNS/PNS clinical criteria and at least two EFNS/PNS supportive criteria
Or
Patient having a muscular autoimmune disease, or a Clarkson syndrome or other autoimmune disease
Currently treated by IVIG

Exclusion criteria :